"0"^^ . " angiogenesis" . "Lymfom z pl\u00E1\u0161\u0165ov\u00FDch bun\u011Bk (MCL) je nevyl\u00E9\u010Diteln\u00E1 agresivn\u00ED forma B-nehodgkinsk\u00E9ho lymfomu. Preklinick\u00E9 testov\u00E1n\u00ED nov\u00FDch protilymfomov\u00FDch l\u00E9\u010Debn\u00FDch strategi\u00ED p\u0159edstavuje z\u00E1kladn\u00ED p\u0159edpoklad pro vytvo\u0159en\u00ED pozd\u011Bj\u0161\u00EDch klinick\u00FDch studi\u00ED. Prvn\u00EDm c\u00EDlem projektu je v\u00FDzkum \u00FA\u010Dinnosti kombinovan\u00E9 angiangiogenn\u00ED terapie, jej\u00ED\u017E protin\u00E1dorov\u00FD mechanismus spo\u010D\u00EDv\u00E1 v potla\u010Den\u00ED n\u00E1dorov\u00E9 neovaskularizace. Dal\u0161\u00EDmi c\u00EDly projektu je anal\u00FDza role receptor\u016F pro VEGF a vybran\u00FDch adhezivn\u00EDch molekul (CD31, CD44) v p\u0159e\u017Eit\u00ED, r\u016Fstu, \u0161\u00ED\u0159en\u00ED a terapeutick\u00E9 odpov\u011Bdi MCL a prognostick\u00FD v\u00FDznam exprese t\u011Bchto molekul na prim\u00E1rn\u00EDch bu\u0148k\u00E1ch pacient\u016F. Experimenty budou prov\u00E1d\u011Bny na my\u0161\u00EDm modelu lidsk\u00E9ho MCL. Studie p\u0159inese preklinick\u00E9 od\u016Fvodn\u011Bn\u00ED pro budouc\u00ED testov\u00E1n\u00ED kombinovan\u00E9 antiangiogenn\u00ED terapie u pacient\u016F s MCL a povede k objasn\u011Bn\u00ED role vybran\u00FDch molekul \u00FA\u010Dastn\u00EDc\u00EDch se angiogeneze v biologii MCL. P\u0159edpokl\u00E1d\u00E1me, \u017Ee v\u00FDsledky studie budou m\u00EDt dopad na vytv\u00E1\u0159en\u00ED nov\u00FDch terapeutick\u00FDch postup\u016F v l\u00E9\u010Db\u011B rezistentn\u00EDch forem MCL u \u010Dlov\u011Bka." . . . "Role angiogeneze v p\u0159e\u017Eit\u00ED, r\u016Fstu, \u0161\u00ED\u0159en\u00ED a terapeutick\u00E9 odpov\u011Bdi lymfomu z pl\u00E1\u0161\u0165ov\u00FDch bun\u011Bk (Mantle Cell Lymphoma, MCL)" . " xenograft" . . . "Mantle cell lymphoma; angiogenesis; tumor microenvironment; xenograft; antiangiogenic therapy"@en . "2015-12-31+01:00"^^ . . "2014-03-21+01:00"^^ . "Role of angiogenesis in mantle cell lymphoma (MCL) survival, growth, spread and response to therapy"@en . "2015-01-22+01:00"^^ . . . "2012-04-01+02:00"^^ . . . . . . "NT13201" . "3"^^ . . "3"^^ . . "1"^^ . "Mantle cell lymphoma" . . "Mantle cell lymphoma (MCL) is incurable B-cell non-Hodgkin lymphoma. Preclinical testing of experimental treatment strategies is requisite for design of future clinical trials. Antiangiogenic molecules appear to be uniquely active in MCL, including temsirolimus and lenalidomide. Treatment approaches targeting angiogenesis, the anti-tumor activity of which lie in blockage of tumor neovascularization and prosurvival angiogenic signaling, cannot be tested in vitro, but require sophisticated animal models. In the first part of the project we will test anti-MCL efficacy of combined antiangiogenic therapy. In the second part of the project we wil analyze role of VEGF receptors and selected adhesion molecules (CD31, CD44) on MCL biology (engraftment, growth, spread) and response to antiangiogenic therapy. Prognostic relevance of these molecules will be determined on primary MCL samples by immunohisochemistry. The results of this project will have direct implications for the therapy of MCL."@en . "1"^^ . . "http://www.isvav.cz/projectDetail.do?rowId=NT13201"^^ . . " tumor microenvironment" .